NCT07605832

Brief Summary

The goal of this quasi-experimental pretest-posttest controlled study is to learn whether moderate-intensity treadmill exercise can improve gait kinematics, walking capacity, and motor performance in preschool children aged 48-72 months with surgically corrected acyanotic congenital heart disease. The main questions it aims to answer are: Does moderate-intensity treadmill training improve gait kinematics, including stride length, walking speed, and double-stance percentage? Does moderate-intensity treadmill training improve walking capacity and balance in children with surgically corrected acyanotic congenital heart disease? Researchers compared children with surgically corrected acyanotic congenital heart disease who received treadmill training with age-matched healthy children to see whether the exercise program could reduce gait, balance, and walking-capacity differences between the groups. Participants with congenital heart disease completed: Four treadmill walking sessions per week for 10 weeks. Moderate-intensity walking at approximately 70% of maximal heart rate. Pre- and post-intervention assessments of gait kinematics using three-dimensional motion analysis. Balance assessment using the Pediatric Balance Scale. Walking capacity assessment using the six-minute walk test.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started May 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 9, 2026

Completed
17 days until next milestone

First Posted

Study publicly available on registry

May 26, 2026

Completed
5 days until next milestone

Study Start

First participant enrolled

May 31, 2026

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2026

Completed
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2026

Completed
Last Updated

May 26, 2026

Status Verified

April 1, 2026

Enrollment Period

3 months

First QC Date

May 9, 2026

Last Update Submit

May 18, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • gait parameters

    Gait parameters, including stride length (cm), speed (meters/minute), and double stance percentage (%) of the dominant leg, were assessed using a 3D motion analysis system.

    basiline pre-test assessment and after 10 weeks of interventions (post-intervention assessment)

Study Arms (2)

congenital heart disease

EXPERIMENTAL

The children in this group received walking sessions weekly for 10 weeks.

Other: treadmill walking sessions

healthy group

NO INTERVENTION

health control group

Interventions

4 sessions of walking on treadmill for 2.5 months

congenital heart disease

Eligibility Criteria

Age48 Months - 72 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • For cyanotic postoperative congenital heart disease group:
  • Children diagnosed with acyanotic postoperative congenital heart disease.
  • Underwent surgical repair for CHD.
  • Has a history of only one surgical intervention.
  • Age between 48 and 72 months.
  • Mentally normal, with an IQ between 85 and 115.
  • For the healthy control group (HCG):
  • For healthy children aged 48 to 72 months. Full school attendance. Full participation in social and recreational activities. Parents/guardians provided written informed consent.

You may not qualify if:

  • Children were excluded if they had:
  • Genetic disorders.
  • Severe neurological disorders.
  • Cyanotic congenital heart disease.
  • Perinatal complications.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Amira Hussin Mohammed

Gamasa, 35712, Egypt

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 9, 2026

First Posted

May 26, 2026

Study Start

May 31, 2026

Primary Completion

August 31, 2026

Study Completion

September 1, 2026

Last Updated

May 26, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

All the required data that support the conclusion will be available when requested.

Locations